DrugDashboards

Deferoxamine

Deferoxamine Mesylate · DEFEROXAMINE MESYLATE 95 mg/mL · Injection, Powder, Lyophilized, For Solution · Intramuscular; Intravenous; Subcutaneous · Fresenius Kabi USA, LLC

NDC 63323-0597-10 · 1 VIAL in 1 BOX / 5.3 mL in 1 VIAL · ANDA · View full market →

The short version

5 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$10.02per billing unit (500 MG)HCPCS J0895 · Jul 1, 2026
  • Part D plans paid (avg)$19.98per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$11.06per unitFresenius Kabi, LLC · May 15, 2025

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$14.76
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 500 MG
$10.020
HCPCS J0895 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$68,118
331 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $290.47 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA078718
TE code
AP
Approval date
Sep 15, 2009
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Deferoxamine Mesylate (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Apotex Corp.DEFEROXAMINE MESYLATE 500 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.DEFEROXAMINE MESYLATE 2 g/1Jul 15, 2026Sep 2, 2026
Gland Pharma LimitedDEFEROXAMINE MESYLATE 2 g/1Jul 15, 2026Sep 2, 2026
Gland Pharma LimitedDEFEROXAMINE MESYLATE 500 mg/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.DEFEROXAMINE MESYLATE 2 g/1Jul 15, 2026Sep 2, 2026
Novartis Pharmaceuticals CorporationDEFEROXAMINE MESYLATE 500 mg/1Jul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCDEFEROXAMINE MESYLATE 95 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Deferoxamine — NDC 63323-0597-10," retrieved September 3, 2026, https://drugdashboards.com/drug/63323059710.

Free to cite with attribution — see how the data is put together.